Navigation Links
ViroPharma To Acquire Lev Pharmaceuticals
Date:7/15/2008

f clinical practice experience in Europe. C1-INH depletion is also implicated in a number of other serious inflammatory disorders.

Hereditary angioedema, or C1-INH deficiency, is a dangerous and potentially deadly inflammatory disease affecting up to 10,000 patients in the United States, caused by a genetic deficiency in an essential protein called C1 esterase inhibitor. Clinical studies have shown that prophylactic C1 inhibitor replacement therapy with Cinryze can significantly reduce the severity, duration and frequency of HAE attacks.

"This transaction is consistent with ViroPharma's stated objective of broadening our portfolio of therapies for serious life-threatening conditions in selected specialty markets," commented Vincent Milano, ViroPharma's president and chief executive officer. "Lev's orphan drug Cinryze(TM) is a life-saving therapy treating a very dangerous disease. This opportunity provides a clear strategic fit with ViroPharma: Cinryze targets a market that is addressable with modest additional infrastructure and further serves patients suffering from a disease with few treatment options. We are very pleased to add the expertise of Lev to our organization, and Cinryze to our growing portfolio of options for underserved patient populations with critical and urgent needs."

"We believe this transaction recognizes the value we have created at Lev and provides our shareholders with attractive financial terms, through the upfront payment and the opportunity to continue to share in the success of Cinryze(TM) through the ownership of ViroPharma shares and the contingent value rights," commented Judson Cooper, Lev's chairman of the board. "Leveraging the combined resources of both companies not only strengthens our C1 inhibitor development platform, but also underscores our commitment to serving patients with critical unmet medical needs."

Transaction Terms

Under the terms of the merger agreement, ViroPharma will acquire the
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. ViroPharma to Present at Two Upcoming Healthcare Conferences
2. ViroPharma Provides 2008 Outlook
3. ViroPharma to Present at the BIO CEO & Investor Conference
4. ViroPharma to Release 2007 Fourth Quarter and Full Year Financial Results on February 27, 2008
5. ViroPharma to Present at the Susquehanna Financial Group Second Annual Significant Options in Healthcare Conference
6. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
7. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
8. ViroPharma to Present at Two Upcoming Healthcare Conferences
9. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
10. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
11. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... -- BioNano Genomics, Inc., the leader in genome mapping, announced ... commercial officer. Salyer has more than 20 years of ... sciences. At BioNano, Salyer will oversee the commercialization of ... assemble a comprehensive view of complex genomes to help ... located in the United States , ...
(Date:3/26/2015)... ReliantHeart, Inc., an innovative supplier of advanced mechanical ... transit-time flow measurement solutions, are collaborating on a miniature ... the HeartAssist5® Left Ventricular Assist Device (LVAD). ... and peace of mind. , The Transonic flow ... 1/6th of the power required by earlier flow board ...
(Date:3/25/2015)... Russia,s pharmaceutical market is one of the ... to its absolute size, plus a growing economy and ... from Business Monitor International. The Russian market is set ... pharmaceutical market, with growth estimates around 10-15% annually reaching ... About Green Cross Green Cross ...
(Date:3/25/2015)... London, UK (PRWEB) March 25, 2015 ... pervasive uptake of smartphones have fuelled social media ... population being currently engaged in social networking. Insurance ... exhaustively to communicate with clients and promote a ... the globe over are increasingly exploiting social networking ...
Breaking Biology Technology:BioNano Genomics Appoints Terry Salyer as Chief Commercial Officer 2BioNano Genomics Appoints Terry Salyer as Chief Commercial Officer 3LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 2LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 3Social Media Role in Global Insurance Industry Examined by Timetric in New Market Research Report Published at MarketPublishers.com 2Social Media Role in Global Insurance Industry Examined by Timetric in New Market Research Report Published at MarketPublishers.com 3
... a key role in solving global dependency on fossil ... of Mechanical, Aerospace, and Nuclear Engineering at Rensselaer Polytechnic ... at room temperature. Rafiee has created a ... capacity far exceeding any other known material. For this ...
... ... ... ... ...
... ... ... ... ...
Cached Biology Technology:Helping hydrogen: Student inventor tackles challenge of hydrogen storage 2Helping hydrogen: Student inventor tackles challenge of hydrogen storage 3Helping hydrogen: Student inventor tackles challenge of hydrogen storage 4NeoStem Enters into SRA with University of Michigan; Funding from NIH Stem Cell Research Grant 2NeoStem Enters into SRA with University of Michigan; Funding from NIH Stem Cell Research Grant 3NeoStem Enters into SRA with University of Michigan; Funding from NIH Stem Cell Research Grant 4NeoStem Enters into SRA with University of Michigan; Funding from NIH Stem Cell Research Grant 5NeoStem Enters into SRA with University of Michigan; Funding from NIH Stem Cell Research Grant 6NeoStem Enters into SRA with University of Michigan; Funding from NIH Stem Cell Research Grant 7NeoStem Enters into SRA with University of Michigan; Funding from NIH Stem Cell Research Grant 8NeoStem Enters into SRA with University of Michigan; Funding from NIH Stem Cell Research Grant 9Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 2Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 3Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 4Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 5Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 6Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 7Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 8Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 9Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 10Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 11Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 12Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 13Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 14Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 15Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 16Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 17Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 18Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 19Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 20Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 21Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 22Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 23Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 24Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results 25
(Date:3/23/2015)... --  HOYOS Labs , a leading global authentication infrastructure ... Company will demonstrate multiple biometrics-based technologies under its identity ... on March 23 through 25, 2015, in ... IEEE Biometric Open Protocol Standard; free biometrics-based consumer app, ... system. BOPS was invented by HOYOS Labs and contributed ...
(Date:3/20/2015)... 2015 Research and Markets ( ... "India Sensors Market Forecast and Opportunities 2020" ... sensor market is projected to grow at a ... electronics, automotive, industrial and healthcare sectors are the ... In addition, adoption of MEMS technology in sensors ...
(Date:3/20/2015)... Research and Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ) has ... Strategic Business Report" report to their offering. ... US$ Thousands. The report provides separate comprehensive analytics for the ... , Europe , Asia-Pacific ... Latin America . Annual estimates and forecasts ...
Breaking Biology News(10 mins):HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5
... 2010) -- New technologies such as microarrays, next-generation ... quantitative reasoning among biologists when designing experiments and interpreting ... statistical assumptions and methods that need to be appreciated ... and exploited fully. Statistics at the Bench: ...
... identified two cellular proteins that are important factors in hepatitis ... approval of new and less toxic treatments for the disease, ... estimated 270 to 300 million people worldwide are infected with ... can have significant side effects. A new drug targeting ...
... gleaned a key insight into the molecular beginnings of age-related ... the elderly, by determining how two key proteins interact to ... paper to be published in a forthcoming issue of the ... the first time how a common blood protein linked to ...
Cached Biology News:New handbook for biologists who need more competence or confidence in statistics 2Natural compound blocks hepatitis C infection 2New research findings may help stop age-related macular degeneration at the molecular level 2